As of Jul 28
| +3.08 / +2.02%|
The 17 analysts offering 12-month price forecasts for Edwards Lifesciences Corp have a median target of 157.00, with a high estimate of 185.00 and a low estimate of 127.00. The median estimate represents a +0.77% increase from the last price of 155.80.
The current consensus among 21 polled investment analysts is to Buy stock in Edwards Lifesciences Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.